Comparison of anticholinergic burden with chronic polypharmacy on functional decline and mortality in Korean older people: a retrospective nationwide cohort study

Table 4 Adjusted HR of all-cause mortality of anticholinergic burden score and chronic polypharmacy combined with TUG test

		TUG	Number	Event	Duration (PY)	IR^a	Crude HR (95% CI)	Model 1^b aHR (95% CI)	Model 2^c aHR (95% CI)
KABS score	0	Normal	23,311	1,553	276,219	8.8	1	1	1
		Abnormal	14,250	1,155	107,578	10.1	1.22 (1.13–1.31)	1.30 (1.16–1.46)	1.28 (1.14–1.43)
	1–2	Normal	1,220	129	9,068	12.0	1.62 (1.35–1.94)	1.41 (1.06–1.88)	1.38 (1.03–1.83)
		Abnormal	937	122	6,937	14.7	2.00 (1.66–2.41)	2.31 (1.71–3.14)	2.13 (1.56–2.90)
	≥ 3	Normal	582	70	4,248	13.0	1.87 (1.48–2.39)	1.78 (1.21–2.61)	1.63 (1.11–2.40)
		Abnormal	480	69	3,510	15.5	2.24 (1.76–2.85)	2.65 (1.77–3.98)	2.42 (1.61–3.64)
	P for trend						< 0.001	< 0.001	< 0.001
Chronic polypharmacy	No	Normal	24,172	1,615	182,744	8.8	1	1	1
Chronic polypharmacy		Abnormal	14,976	1,242	113,013	10.4	1.24 (1.15–1.34)	1.35 (1.21–1.51)	1.32 (1.18–1.48)
	Yes	Normal	941	137	6,792	17.1	2.30 (1.93–2.74)	2.26 (1.73–2.96)	1.78 (1.34–2.37)
		Abnormal	691	104	5,012	17.1	2.36 (1.94 − 2.89)	2.44 (1.73–3.44)	2.02 (1.42–2.87)
	P for trend						< 0.001	< 0.001	< 0.001

Abbreviations: KABS, Korean Anticholinergic Burden Scale; PY, person-years; IR, incidence rate; HR, hazard ratio; CI, confidence interval; aHR, adjusted hazard ratio; TUG, Timed Up and Go test
^aIncidence per 1000 person-years
^bModel 1 was adjusted for sex, body mass index, income, smoking status, alcohol consumption, and physical activity
^cModel 2 was adjusted for sex, body mass index, income, smoking status, alcohol consumption, physical activity, depressive mood, cognitive impairment, activities of daily living, falls, hypertension, diabetes, and dyslipidemia
Abbreviations: TUG, Timed Up and Go

ISSN: 1471-2318